Imatinib Mesylate Tablet, Film Coated
Product Images NDC 60687-882

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 60687-882). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Imatinib Mesylate Tablet Blister (100 mg Imatinib Mesylate Tablet Blister)

FDA Label Image

100 mg Imatinib Mesylate Tablets Carton (100 mg Imatinib Mesylate Tablets Carton)

This text provides detailed information about Imatinib Mesylate tablets, with NDC 60687-882-21. Each tablet contains 118.6 mg of Imatinib Mesylate. The usual dosage should be determined based on prescribing information. These tablets should be stored at 20-25°C (68-77°F) with excursions permitted between 15-30°C (53-66°F). The product should be protected from moisture. It is essential not to use the tablets if the packaging is torn or broken. The product was distributed by American Health Packaging in Columbus, Ohio.*

FDA Label Image

Ahp88221

FDA Label Image

Figure 1: Progression Free Survival (itt Principle) (Figure1)

This data appears to be related to a clinical trial involving Imatinib Mesylate and IFN+Ara-C arms, assessing the progression of patents. The hazard ratio is calculated to be 0.378 (CI: 0.291-0.493) with a significant p-value of <0.0001 from the Log-rank Test. Progression status is delineated based on censoring at discontinuation and last follow-up. The graph shows the trend in months since randomization.*

FDA Label Image

Figure 2: Time To Progression To Ap Or Bc (itt Principle) (Figure2)

Available data shows that there were 35 patients who progressed to accelerated phase (AP) or blast crisis (BC), while 137 patients were censored at discontinuation and 381 were censored at fast follow-up. The Hazard Ratio [95% CI] indicates a significant difference between the Imatinib Mesylate Arm and the IFN+Ara-C arm. The hazard ratio is 0.474 with a confidence interval of [0.312, 0.722], and the Log-rank Test P-value is less than 0.001. The data spans over 60 months since randomization.*

FDA Label Image

Figure 3: Study 1 Recurrence-free Survival (itt Population) (Figure3)

This text appears to be related to a medical study evaluating the probability of being alive and recurrence-free for patients taking Imatinib 400mg versus a placebo. The data includes the number of patients at risk and the survival time in months. The study involves a comparison between the two groups, Imatinib and Placebo, showing different numbers of patients and their corresponding survival times.*

FDA Label Image

Figure 4: Study 2 Recurrence-free Survival (itt Population) (Figure4)

This is not available.*

FDA Label Image

Figure 5: Study 2 Overall Survival (itt Population) (Figure5)

FDA Label Image

Structural Formula (Structural Formula)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.